Funding - POCTRN

Find Funding

Current Funding Opportunities

Please sign up for our newsletter to be notified when new opportunities are launched.

POCTRN 2024 Solicitation: Now Accepting Applications

Do you have a groundbreaking point-of-care technology in need of development? The National Institute of Biomedical Imaging and Bioengineering’s (NIBIB) Point-of-Care Technology Research Network (POCTRN) is pleased to announce six new funding opportunities from its centers.

Embark on a journey to advance the development of transformative point-of-care technologies through collaborative efforts that seamlessly blend scientific and technological expertise with clinical needs.

Learn more and apply >

 

Past Funding Opportunities

ITAP for Diagnostic Mpox Lesion Panel

NIBIB is soliciting proposals to address the diagnostic needs for point-of-care (POC) lesion panel tests. This includes tests intended for the direct detection and differentiation of mpox virus (MPXV), herpes simplex virus types 1 and 2 (HSV1/2), Treponema pallidum (Syphilis), and varicella-zoster virus (VZV) in lesion swab specimens (“lesion panel”).

NIBIB plans to support analytical and clinical testing to accelerate test validation and regulatory review of POC tests. These efforts will help facilitate rapid production and commercialization of mpox lesion panel tests in the US.  NIBIB will consider applications from test manufacturers with existing technologies for detection of:

  • MPXV and HSV1/2 only
  • MPXV and HSV1/2 in combination with VZV and/or Syphilis

NIBIB will only consider tests that can quickly reach design lock, scale production, and can demonstrate performance to support authorization. NIBIB will not consider applications for tests of prior MPXV, HSV1/2, VZV, and/or Syphilis infection or immunity (e.g. anti-MPXV antibodies).

Learn More >

Hepatitis C Virus Point-Of-Care Diagnostics

ITAP is now accepting proposals on a rolling basis for POC tests for the direct detection and quantitation of the hepatitis C virus RNA. Test manufacturers with existing technologies for HCV RNA detection and quantitation that can quickly enter production and meet the U.S. Food and Drug Administration's (FDA’s) performance/quality standards are encouraged to apply. ITAP will help accelerate the validation, regulatory authorization, and commercialization of select HCV RNA POC diagnostics. While priority will be given to HCV tests, proposals may also include hepatitis B virus (HBV) qualitative DNA POC tests given the importance of knowing the presence of detectable HBV DNA in a patient undergoing treatment for hepatitis C.

Learn more >

ITAP Multiplex Point-of-Care (POC) Diagnostic Tests

ITAP is now accepting applications for proposals to accelerate the validation, regulatory authorization and commercialization of innovative point-of-care (POC) tests that can detect a combination of COVID-19 and Flu A/B (including pan A/B). Proposals for combination POC tests may include respiratory syncytial virus (RSV) but is not required.

Learn more >

Advanced Platforms for HIV Viral Load Testing at the Point-of-Care

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) announces that its Point-of-Care Technology Research Network (POCTRN) is soliciting proposals to further advance HIV viral load detection technologies in order to fill specific unmet national and global needs. Under this solicitation, NIBIB is seeking proposals to accelerate the validation and prototyping of innovative HIV VL testing platforms that are designed for use at the point-of-care that fill unmet national and global needs with a level of analytical performance, especially for VL limit of detection, that facilitates monitoring PWH on ART and accurately assessing infectiveness. Proposed solutions with optimized design, performance, and sample collection for infants are welcome but not required, as are platforms that employ innovative sampling methods.

Learn more >

High-Performance COVID-19 Rapid Tests Fast-Track Program to Advance U.S. COVID-19 Testing Capabilities

The RADx Coordination Center at CIMIT, on behalf of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), is soliciting proposals to further advance next-generation (next-gen) over-the-counter (OTC) and point-of-care (POC) testing technologies for COVID-19 under its Rapid Acceleration of Diagnostics (RADx) fast-track program.

Learn more >

COVID-19 Home Tests Accessible to People with Disabilities Fast-Track Program to Advance U.S. COVID-19 Testing

The RADx Coordination Center at CIMIT, on behalf of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), is soliciting proposals for accessible over-the-counter (OTC) testing technologies for COVID-19 under its Rapid Acceleration of Diagnostics (RADx) fast-track program.

Learn more >

RADx Tech for Maternal Health Challenge

The National Institutes of Health is offering up to $8 million in cash prizes to accelerate development of technologies to improve maternal health outcomes for those who live in areas lacking access to maternity care. The Rapid Acceleration of Diagnostics Technology (RADx® Tech) for Maternal Health Challenge prioritizes home-based or point-of-care diagnostic devices, wearables and other remote sensing technologies to improve postpartum healthcare in these regions. 

Learn more >

ITAP for Monkeypox

ITAP is accepting new proposals on a rolling basis to address the diagnostic needs of the monkeypox outbreak. ITAP support will help accelerate the validation, regulatory authorization, and commercialization of point-of-care (POC) and home monkeypox virus tests.

Learn more >

POCTRN Solicitation 2022 
New Funding Opportunities From Our Four Centers

Do you have a promising point-of-care technology in need of further development?

The NIH’s Point-of-Care Technology Research Network (POCTRN) drives the development of point-of-care technologies through collaborative efforts that merge scientific and technological capabilities with clinical need. 
 

Learn more >

RADx Tech II: Fast-Track Program to Advance U.S. COVID-19 Testing Capabilities

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is announcing today that its Point-of-Care Technology Research Network (POCTRN) is soliciting proposals to further advance SARS-CoV-2 testing technologies in order to fill specific unmet national needs. Unmet needs include but are not limited to point-of-care/over-the-counter tests with lab performance, tests for multiple pathogens, and tests adaptable to emerging variants.

Learn more >

NIH Blueprint MedTech Pilot Award to Accelerate Early-Stage Neurotechnologies

The NIH has established a 1-year pilot program to support early translation of medical device interventions for diseases of the central and peripheral nervous systems.

Learn more >

POCTRN 2021 Call for Proposals

Fast-Track Program for COVID-19 Test Development and Distribution

NIBIB Announces three COVID-19 Notices of Special Interest

In response to the COVID-19 crisis, NIBIB has released multiple Notices of Special Interest. This includes: administrative supplements and emergency competitive revisions funding for current grantees; SBIR/STTR opportunities; and investigator-initiated research opportunities. Current grantees and new applicants are encouraged to apply immediately. The goal is to support proposals that accelerate research, translation, and commercialization of technologies relevant to COVID-19. Researchers can read NIBIB Director Bruce Tromberg’s message on how bioengineers can help thwart the COVID-19 pandemic. 

NIH Announces $1 Million Prize Competition to Target Global Disease Diagnostics

POCTRN 2020 Call for Proposals

POCTRN 2019 Call for Proposals

RADx: Rapid Acceleration of Diagnostics

In response to the COVID-19 pandemic, the Rapid Acceleration of Diagnostics (RADx®) initiative was formed to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19.

ABOUT RADx

In the News 

Two New Over-the-Counter At-Home COVID-19 Tests Brought to U.S. Market Quickly by Biden-Harris Administration

New HHS actions add to Biden administration efforts to increase access to easy-to-use over-the-counter COVID-19 tests

NIH RADx initiative expands COVID-19 testing innovation for additional types of rapid tests

The need for new test verification and regulatory support for innovative diagnostics

NIH-funded screening study builds case for frequent COVID-19 antigen testing

RADx partnerships speed new COVID testing

One Year of RADx Tech Success

Publication reveals essential ingredients of the groundbreaking NIH RADx national diagnostics effort 

Innovative COVID-19 Testing RADx Tech Reports Unveiled in Special Issue of IEEE Open Journal of Engineering in Medicine and Biology

Luminostics Announces FDA Authorization and Production Scale-Up of US-Manufactured Smartphone-Based COVID-19 Rapid Test

RADx Expects COVID-19 Portfolio to Accelerate an Era of At-Home Infectious Disease Testing (Login Required)

VIC Foundry, Inc. Receives NIH RADx Funding for Development of an At-home Molecular Diagnostic Test for COVID-19

Ceres Nanosciences Opens Advanced Particle Manufacturing Plant in Northern Virginia to Expand Nanotrap® Particle Manufacturing Capacity for COVID-19 Testing

COVID-19 Testing: Three Breakthrough Solutions in the RADx Initiative

NIH Director: Collaboration Amid Chaos, and Biden’s First 100 Days - How Francis Collins sees the COVID response changing with the new administration

The National Strategy From the COVID-19 Response and Pandemic Preparedness

Winners of HHS Design-a-thon to Develop Innovative Digital Health Tools for COVID-19 At-Anywhere Diagnostic Tests Announced

The Need for More and Better Testing for COVID-19